biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Brain: New standard of care?

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Feb 21, 2023 10:10am

347 Views

Post# 35296154

Brain: New standard of care?

DNLI data this week includes:

Title: DNL310 normalizes primary storage substrates and biomarkers of lysosomal dysfunction in neuronopathic MPS II: 2-year interim analysis of a phase 1/2 study (Poster #48)
Session: Contemporary Forum – Poster Session VII
Date: Saturday, February 25, 2023
Time: 3:00 – 4:00 PM Eastern Time

Title: DNL310-treated study participants with MPS II show improvements in toileting abilities
Session: Contemporary Forum Poster Presentations
Date: Saturday, February 25, 2023
Time: 4:00 – 5:00 PM Eastern Time

---------

BTI has anticipated its Hunter data in Q2.
Mei Mei, Saltarelli, and Rathjen are also on Chiesi's xB3 Advisory Board.